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Longstanding Crystalline Retinopathy Secondary to Intravitreal Triamcinolone
Injection
Abstract
Background: Crystalline retinopathy has many disparate etiologies with varying potentials in visual
outcome. Due to the potential severity of these outcomes, differentiation of etiology is critical to guide
both follow up and treatment regimen. Diagnosis can be facilitated with a thorough medical history,
clinical presentation, and imaging such as optical coherence tomography (OCT).
Case Report: This case demonstrates a rare incidence of crystalline retinopathy in a 65-year-old male
attributed to a single intravitreal triamcinolone acetonide (IVTA) injection with 8 year follow up data,
followed by a review of other types of crystalline retinopathy secondary to pharmaceutical agents.
Conclusion: A complete case history, including medications, systemic disorders and surgical history are
critical. Ancillary testing, such as OCT can be diagnostic. This patient’s history of IVTA injection for
diabetic macular edema and the OCT showing preretinal hyperreflective refractiles lead to the diagnosis
of triamcinolone crystalline retinopathy.

Keywords
Crystalline retinopathy, intravitreal Kenalog/triamcinolone

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This case report is available in Optometric Clinical Practice: https://athenaeum.uiw.edu/optometric_clinical_practice/
vol4/iss1/2

Thomas and Curry: Crystalline Retinopathy Secondary to Intravitreal Triamcinolone

INTRODUCTION
The differentials for crystalline retinopathies secondary to pharmaceutical agents
are diverse and range from oral supplements to cancer treatments.1 In addition,
crystalline retinopathies may occur due to genetic disorders, degenerative
processes, or be iatrogenic.1 Many of these cause a chronic yet benign presentation,
while others lead to decreased vision secondary to retinal edema or atrophy. Visual
outcome and possible treatment of crystalline retinopathy varies depending upon
etiology. Thorough clinical case history including medication review, fundoscopic
examination, and multimodal imaging can differentiate pathologies. One potential
etiology of crystalline retinopathy is triamcinolone (Kenalog) which was first
detailed in 2010 after intravitreal injections for macular edema and, to date, few
studies have monitored for potential long term sequalae.2 This paper will review a
case of crystalline retinopathy secondary to one intravitreal injection of
triamcinolone while also reviewing and highlighting contrasting features of
differential medication related crystalline retinopathies.
CASE REPORT
A 65-year-old African American male presented for an annual diabetic eye exam.
He reported that he had been diagnosed with type 2 diabetes in 1997 and is currently
treated with insulin. His fasting glucose was unknown; however, his hemoglobin
A1c had been measured earlier that week at 9.6%. The patient also had a positive
history of hyperlipidemia, treated with atorvastatin, and hypertension, treated with
carvedilol, hydrochlorothiazide, and losartan. His only known medical allergy was
lisinopril. He reported a limited surgical history consisting of intravitreal injection
procedures. Ocular history was remarkable for refractile retinal deposits and a
misdiagnosis of asteroid hyalosis. This was first clinically noted in 2012 and
photographed in 2014. During the 2011 exam, the patient’s best corrected visual
acuity had dropped from 20/20 right eye (OD) and left eye (OS) to 20/25 OD and
OS with clinically significant macular edema, as well as exudates and
microaneurysms within 500um of the fovea. Macular optical coherence
tomography (OCT) confirmed swelling which was treated with a single dose of
intravitreal triamcinolone OD. Further treatment was required with intravitreal
ranibizumab OS between 2011 and 2014 for the development of diabetic macular
edema. The crystals appeared no earlier than 2014, as evidenced by fundus photos
in Figure 1.
At the present visit, visual acuities were 20/20-1 OD and OS. Entrance testing
was unremarkable. Intraocular pressures were measured as 21/19 mm Hg OD/OS
with applanation tonometry and slit lamp examination was within normal limits.
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Both optic nerves were pink and distinct with a cup to disc ratio of 0.30 in each eye.
The macula of the right eye was remarkable for yellow crystalline deposits which
were absent from the left eye, as shown in Figures 1 and 2. There were isolated
scattered microaneurysms just beyond the arcades in both eyes. The peripheral
retina was unremarkable in both eyes.

Figure 1: Multi-color photos obtained with Heidelberg OCT in October 2019 show crystalline
deposits throughout the macula OD which are absent OS. The central white dots are artifacts OU

Figure 2: Baseline fundus photo with a Topcon retinal camera from 2014 showing peri-foveal
refractile yellow deposits OD
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The photos of the posterior pole were obtained (Figure 1) to compare to baseline
photos from 12/30/14 (Figure 2) and showed grossly stable crystalline deposits OD
with slight migration of crystals. Macular OCT (Heidelberg) showed small cystic
pockets of edema near the fovea OS (not pictured) and was also remarkable for
hyperreflective crystalline deposits on the posterior hyaloid face of the vitreous OD
(Figure 3). Most of the crystals were still flush with the surface of the internal
limiting membrane (ILM) but followed the vitreous in areas of early vitreous
detachment (Figure 4). The crystals were also visible in black and white photos
(Figure 5).

Figure 3: Heidelberg Spectralis SD-OCT raster scan showing hyperreflective
crystalline deposits on the innermost surface of the retina

Figure 4: Heidelberg Spectralis SD-OCT raster scan showing hyperreflective
crystalline deposits on the posterior hyaloid face
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Due to poor control of his blood sugar and diabetic macular edema OS, the patient
was referred to a retinal specialist for further intervention. While the crystals OD
can be clearly observed in previous fundus photos, they had been mentioned only
as a secondary clinical finding, without determination of etiology. The patient also
had a history of being misdiagnosed with asteroid hyalosis. Diagnosis of crystalline
retinopathy secondary to triamcinolone was made due to the unilaterality and
location of the crystals on OCT combined with the patient’s medical history of
intravitreal injection OD. This was supported by the stability of findings and
excellent visual acuity, and as such was monitored on an annual basis.

Figure 5: Photos showing crystals OD; the white central dot OU and inferior temporal circular
hypopigmentation OD are artifacts

DISCUSSION
Many forms of crystalline retinopathy have a similar fundoscopic appearance,
making them difficult to distinguish without ancillary testing (Table 1). Case
history is critical, particularly regarding past and present medications and systemic
disorders. Imaging techniques are important as well to determine etiology. In fact,
OCT pinpoints the precise location of the crystals, which can vary depending on
the underlying cause.1 However, some disorders are associated with vascular
disturbances, and are best appreciated with forms of angiography such as
fluorescein angiography.1
Triamcinolone (Kenalog) is a steroid indicated to treat chronic cystoid macular
edema (CME) as seen in diabetic patients or after cataract extraction.3–5
Triamcinolone maculopathy is one form of medication induced crystalline
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retinopathy. While supported in clinical literature, there is only a small body of
research concerning the long-term effects of this retinopathy. Two reports detail
six or greater years of follow up data and stability.6,7 This case provides further
documentation and confirms the limited body of longitudinal case reports of
crystals lingering for at least eight years after a single intravitreal triamcinolone
acetonide (IVTA) injection . These findings were first documented in 2010 to be
superficial and refractile in nature, distributed asymmetrically and clustered around
the macula, often with foveal sparing.2 The annular distribution likely follows the
anatomy of the bursa premacularis, a fluid channel in the vitreous anterior to the
macula, which sequesters the crystals centrally.7,8 Multiple sources agree that
crystals can present after both preserved and non-preserved formulations.1,2,6
Crystals can appear anywhere between 7-48 months after injection, and have been
previously documented to remain for at least six to nine years.6,7 The long term
presence of crystals is surprising, as the half-life of triamcinolone is only 3-18 days
and the drug should be entirely eliminated by 3 months. Fine et al hypothesized
that these preretinal crystals unexpectedly persist due to being sequestered within
the bursa macularis. This positioning would also explain crystal migration due to
changes in the posterior hyaloid over time.7
Ancillary testing reveals crystals to be isofluorescent upon both auto-fluorescence
and fluorescein angiography; no vascular defect is characteristic with this
maculopathy.2,7 Macular OCT shows preretinal refractiles on the posterior hyaloid
face following posterior vitreous detachment or on the retinal surface, as above,
unlike most other forms of this retinopathy.1,2 Crystals may slowly migrate over
time and remain attached to the vitreous when it detaches from the retina. In eyes
that have had pars-plana vitrectomy and subsequent IVTA, crystals have been
documented to coalesce along the retinal vasculature, simulating frosted branch
retinal angiitis.9 Given the consistent lack of adverse effects that define
retinopathy, it has been recommended by some that this condition be known as
“drug-induced benign crystalline hyaloidopathy”.6
Tamoxifen is a nonsteroidal estrogen receptor antagonist used to treat breast
cancer that can cause crystalline retinopathy. However, complications are more
common with higher doses, which can occur in patients being treated for brain
cancer, or with long-term use to prevent relapse. This is most commonly seen when
the cumulative dose reaches 100g.10–12 Higher doses are more likely to cause
crystalline retinopathy and CME, which is associated with decreased visual
acuity.11,13,14 Retinopathy is less common now that the standard dosage has been
lowered to <20mg/day; however, lower doses may still lead to pseudocystic
cavitation within the central macula, which can progress to form a macular
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hole.10,13,15 Other less common complications include keratopathy, cataract, and
optic neuritis.15–19

Medication
Triamcinolone
Tamoxifen
Anastrozole

Appearance
iridescent crystals with
perifoveal distribution
fine crystals in dense
peri-foveal ring

OCT location
posterior hyaloid
face
NFL, IPL, CME
common

Gold parafoveal crystals OPL, INL

crystals following
Methoxyflurane arteries throughout
retina
likely benign yellow dot
Allopurinol*
retinopathy
crystals throughout
Flupentixol^
posterior pole
circinate crystals
Nitrofurantoin^ throughout posterior
pole

Outcome
benign
Fair after
CME resolves
mild VA
decrease

RPE

irreversible

isofluorescent

temporary

IPL

mild VA
decrease

superficial and
deep intraretinal
layers

mild VA
decrease

Ganciclovir^

Yellow perifoveal
crystals

no data

Canthaxanthin*

annular, perifoveal
distribution of yellow
crystals

poor due to
intravitreal
overdose

IPL, NFL

benign,
temporary

Lutein^

yellow foveal crystals

inner retinal
layers

benign

Talc

intra-arterial crystals in
posterior pole

inner retinal
layers

typically
benign; can
cause atrophy

Table 1: summary of fundus appearance, OCT findings, and outcome; * Disputed, ^Atypical

Tamoxifen is also likely to worsen type 2 macular telangiectasia as discussed by
Behrens et al, who recommend not treating these patients with tamoxifen. Behrens
et al theorized that this effect could be due to multiple factors that result in
destruction of Müller cells, which have a significant role in retinal structure and
function.18,19 Patients being treated with tamoxifen should have a baseline eye
exam and be followed at least every two years.17 If retinal changes are observed,
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discontinuation of tamoxifen should be discussed with the prescribing provider.
After discontinuation, both keratopathy and CME have been shown to resolve,
though crystals remain. However, some reports indicate that the crystals may
decrease in density with time.12,14 OCT testing is beneficial, showing hyperreflective refractiles in both the nerve fiber layer (NFL) and inner plexiform layer
(IPL).16 FA will show hyperfluorescence of pseudocystic cavitation or CME. FA
damage has been attributed to retinal pigmented endothelial loss as well as Müller
cell loss.1
Anastrozole is an oral nonsteroidal aromatase inhibitor used in the treatment of
breast cancer with documented ocular side effects including retinal hemorrhages,
bilateral optic disc swelling, vitreo-retinal traction, dry eyes and possibly uveitis
and macular edema.20 There is a case report by Weider et al of a patient reporting
blurry vision after treatment with 1 mg/day of anastrozole. The patient was found
to have isofluorescent crystalline deposits at the outer plexiform layer (OPL) and
inner nuclear layer (INL). These crystals presented earlier than those observed
from tamoxifen, at six months rather than twelve months.20 Vision and macular
appearance were unchanged at the six month follow up.
Methoxyflurane is an anesthetic that can cause crystalline retinopathy, however it
is rarely used due to a high risk of kidney damage.1 Crystals typically follow along
the arterial or periarterial vasculature throughout the posterior pole at the layer of
the retinal pigmented epithelium (RPE) rather than concentrating at the fovea.1
This maculopathy is not reversible and vision changes are permanent.1
Other medications have limited case reports of crystalline retinopathy due to
atypical use. Allopurinol is used to reduce uric acid levels in chemotherapy
patients, as well as the treatment of gout and kidney stones.21,22 A single case report
from Cheah et al. detailed a patient with crystalline retinopathy secondary to
allopurinol. However, there are no other reported cases and the medication is
commonly prescribed.21 Dohaney et al. have suggested that this was actually
“benign yellow dot maculopathy” as there are no corresponding changes on the
OCT.22 There are limited reports of crystalline retinopathy secondary to
flupentixol, nitrofurantoin, and ganciclovir. These are rare cases due to unusually
high doses of the medication and have not been documented with standard use.
Flupentixol, an antipsychotic, caused crystalline deposits throughout the posterior
pole, when a patient consumed more than double the maximum recommended dose
for two full years. These crystals were localized on OCT at the IPL23,24
Nitrofurantoin is used to treat and prevent urinary tract infections.16,25 It more
commonly causes extra-ocular motility imbalance, retinal hemorrhaging, and
papilledema. It has also been documented to cause intraretinal crystals in a
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circinate pattern about the macula, associated with decreased visual acuity. 1,25 This
occurred after using 100mg of nitrofurantoin for at least 19 years.25 Overdose of
intravitreal ganciclovir has also been documented to cause toxic crystalline
retinopathy. A patient erroneously received 15mg/0.3mL instead of 2mg/0.04mL,
a dose 8x larger than intended.26 The patient experienced acute and permanent
vision loss with no light perception. Immediate fundus examination revealed
crystalline retinopathy. 26
Oral supplements have been reported to cause crystalline retinopathy.
Canthaxanthin or β-carotene is a naturally occurring carotenoid used as a red dye.
Pharmacologically, it has also been used to treat photosensitivity or as a supplement
to increase sun-tanning.16 The Food and Drug Administration (FDA) does not
approve any oral supplements for sun tanning, including the supplementation of
canthaxanthin; it is only approved in small doses as a color additive in food.27 It
has been documented to cause yellow perifoveal crystals at the level of the
IPL/NFL,16,17,28,29 with conflicting reports as to whether crystals diminish after
cessation.16,28 Patients are asymptomatic and there is no associated decrease in
visual acuity. There is a positive correlation between cumulative dose and
retinopathy at a dose of >3mg.16 However, others refute the claim that
canthaxanthin is the cause of this retinopathy and were unable to replicate the
findings in subsequent case studies.30 There is also a case report of crystalline
retinopathy occurring after high doses of lutein supplementation. Choi et al reported
a patient intaking at least three times the normal dosage of lutein secondary to 20mg lutein supplement and a diet with an unusually high percentage of lutein rich
foods. Over an eight-year time period the patient developed yellow macular
crystals.31 Lutein is used in the AREDS 2 formulation, a supplement commonly
prescribed by eye care providers for patients with macular degeneration, which
includes 10mg lutein. Crystalline retinopathy has not been reported as a side effect
of AREDS 2 when used at recommended doses but may be considered a differential
when taken in association with extreme diets.
Talc retinopathy is characterized by small, irregular yellow refractile bodies
contained predominantly in small retinal arterioles of the posterior pole.1,32 These
particles are introduced from snorted or intravenous drug use of crushed oral
medications used to make methamphetamine.1,33 Patients are typically
asymptomatic. Talc rarely causes non-proliferative vascular changes and even
more rarely causes proliferative changes that would require treatment. OCT reveals
that refractiles lie within the inner retina. FA is remarkable only if there is ischemia.
Chronic areas of ischemia can develop into atrophy. Particles are stationary and
have not been documented to change with time.34
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CONCLUSION
A wide range of pharmaceuticals can cause crystalline retinopathy, with varying
visual outcomes. Given this, correct differentiation is critical to determining
appropriate treatment. A complete case history, including past and present
medications, systemic disorders and surgical history are critical. Ancillary testing,
such as OCT can be diagnostic depending on the condition. In this case, the
patient’s history of IVTA for diabetic macular edema and the OCT showing
preretinal hyperreflective refractiles were diagnostic for triamcinolone crystalline
retinopathy. This case adds to the body of literature and confirms the lone preexisting report documenting stability of triamcinolone crystalline retinopathy over
an eight-year time period. During this time period, the patient has demonstrated
stable 20/20 vision OD/OS without changes to fundus appearance.
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